Last reviewed · How we verify

NCT06346327

Clinical Significance Of Intermittently Absent End-Diastolic Flow Of The Fetal Umbilical Artery On Perinatal And Neonatal Outcomes Dr. Zeynep Kayaoğlu Yıldırım Dr. Alperen İnce Dr Gökhan Bayanmelek Dr Gökhan Bolluk

Completed Last updated 4 April 2024
What this trial tests

trial in Absent End-Diastolic Flow Of The Fetal Umbilical Artery in 137 participants. Completed in 30 October 2023.

Timeline
1 June 2020
Primary endpoint
31 August 2023
30 October 2023

Quick facts

Lead sponsorBaşakşehir Çam & Sakura City Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment137
Start date1 June 2020
Primary completion31 August 2023
Estimated completion30 October 2023
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Başakşehir Çam & Sakura City Hospital

Who can join

Adults 18 to 45, female only, with Absent End-Diastolic Flow Of The Fetal Umbilical Artery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective: This study aimed to estimate the risk of adverse perinatal outcomes among pregnant patients with intermittently absent (iAEDF) and persistently absent end-diastolic umbilical artery flow (pAEDF). The fetal risks associated with persistently absent end-diastolic flow have been described. However, the risks associated with intermittent absent end-diastolic flow are not well-known. Study design: We performed a retrospective cohort study of patients diagnosed with the iAEDF or pAEDF at our institution from 2020 to 2023. Fetuses were classified under two categories: iAEDF group and pAEDF group.Neonatal outcomes, demographic information, pregnancy outcomes and pregnancy complications were compared between patients with iAEDF and those with pAEDF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Başakşehir Çam & Sakura City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06346327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing